Ausgabe 3/2022
Inhalt (19 Artikel)
CAR-T cells—Real-time experience applying CAR-T cells—What we have learned so far
- editorial
Hildegard Greinix
Neoadjuvant treatment for solid tumors—the earlier, the better
- editorial
Rupert Bartsch, Wolfgang Hilbe
Real time experience applying CAR T-cells for B-cell lymphoma—What we have learned so far: Acute toxicity management
- short review
Emine Kaynak, Johannes Clausen
CAR T cells in multiple myeloma: Where we stand and where we might be going
- short review
Niklas Zojer, Martin Schreder, Heinz Ludwig
Applicability of ESMO-MCBS and ESCAT for molecular tumor boards
- Open Access
- review
Ladislaia Wolff, Barbara Kiesewetter
Molecular profiling leading to personalized treatment in breast cancer
- Open Access
- short review
Eva Valentina Klocker, Marija Balic, Günther Steger
Molecular profiling in lung cancer
- Open Access
- short review
Laurenz Nagl, Georg Pall, Dominik Wolf, Andreas Pircher, Lena Horvath
Neoadjuvant treatment in non-small-cell lung cancer—the earlier, the better
- Open Access
- short review
Angelika Terbuch, Gudrun Absenger
Neoadjuvant treatment of pancreatic ductal adenocarcinoma
- short review
Katharina Kosma, Sabine Thalhammer, Thomas Gruenberger
Neoadjuvant treatment in solid tumors—the earlier, the better in breast cancer
- short review
Renate Pusch
Breast implant-associated anaplastic large-cell lymphoma: a European case report and literature review
- case report
Federico Ghidinelli, Luigi Filippini, Paola Porsio, Federico Canzi, Rino Balzano, Elisa Flocchini, Anna Bianchi
Breast implant-associated anaplastic large-cell lymphoma—update on challenges, advances and opportunities
- comment
Andreas Pircher, Roberto N. Miranda
Essential news and practice changing trials in oesophageal, gastroesophageal junction and gastric cancer in 2021
- short review
Patrick Reimann, Thomas Winder
Multiple myeloma with central nervous system relapse: a case report
- case report
Petra Marics, Wolfgang Pokieser, Nikolaus Neubauer, Georg Slavka, Wolfgang Hilbe, Martin Schreder
Systemic inflammatory response index is a prognostic biomarker in unresectable pancreatic adenocarcinoma and identifies patients for more intensive treatment
- original report
Sara Dâmaso, Rita Paiva, Inês Pinho, Miguel Esperança-Martins, Raquel Lopes Brás, Cecília Melo Alvim, António Quintela, Ana Lúcia Costa, Luís Costa
Publisher Correction: Brain metastases: new systemic treatment approaches
- Open Access
- Publisher Correction
Ariane Steindl, Anna Sophie Berghoff
